Humasis Co

Humasis Co EBITDA Margin

The EBITDA Margin of Humasis Co (205470.KQ) as of Nov 10, 2026 is -46.64 %. In the previous year, EBITDA Margin was -173.67 % — a change of -73.14% (higher).

EBITDA Margin

-46.64 %

YoY

-73.14%

Last updated:

EBITDA Margin of Humasis Co is 2025 -46.64 % . EBITDA Margin of Humasis Co was 2024 -173.67 % . It decreases by -73.14% higher compared to the previous year.

The Humasis Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-9.99 KRW
Jan 1, 2019
-8.64 KRW
Jan 1, 2020
56.00 KRW
Jan 1, 2021
61.19 KRW
Jan 1, 2022
44.50 KRW
Jan 1, 2023
-432.20 KRW
Jan 1, 2024
-173.67 KRW
Jan 1, 2025
-46.64 KRW
The Humasis Co EBITDA Margin history
YEAREBITDA MarginYoY
-46.64 %-73.14%
-173.67 %-59.82%
-432.20 %-1,071.15%
44.50 %-27.26%
61.19 %+9.25%
56.00 %-748.49%
-8.64 %-13.56%
-9.99 %+1,128.50%
-0.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

EBITDA Margin of Humasis Co is -46.64 % in 2025.

EBITDA Margin of Humasis Co changed from -173.67 % to -46.64 %, representing a -73.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Humasis Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Humasis Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Humasis Co